Active Ingredient(s): Ceritinib
FDA Approved: * April 29, 2014
Pharm Company: * NOVARTIS PHARMS
Category: Cancer

Ceritinib (INN,[2] trade name Zykadia /zakedi/ zy-KAY-dee-, from Novartis) is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC).[3] It was developed by Novartis and received FDA approval for use in April 2014.[3].Ceritinib is also sold under the brand name Spexib in few countries by Novartis . Contents 1 Medical uses 2 Adverse effects 3 Interactions 4 Pharmacology 4.1 Mechanism of action 5 Research and de... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Zykadia 150 mg Oral Capsule
NDC: 0078-0640
Novartis Pharmaceuticals Corporation
Zykadia 150 mg Oral Tablet, Film Coated
NDC: 0078-0694
Novartis Pharmaceuticals Corporation